According to a release from Moderna, results of their currently authorized 50 µg booster of Moderna’s COVID-19 vaccine (mRNA-1273) increased neutralizing antibody levels against Omicron approximately 37-fold, compared to pre-boost levels, and a 100-µg dose of the vaccine increased neutralizing antibody levels approximately 83-fold, compared to pre-boost levels.
Separately, the company also announced the safety and tolerability data from the Phase 2/3 study of the 100-µg booster dose of mRNA-1273. Stating that “A 100-µg booster dose of mRNA-1273 was generally safe and well tolerated.
The frequency and nature of solicited systemic and local adverse events 7 days after receiving a booster were generally comparable to those seen after the two-dose primary series. There was a trend toward slightly more frequent adverse reactions following the 100-µg booster dose relative to the authorized 50 µg booster dose of mRNA-1273,” Moderna said.
